Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 8/20 | 0.41 |
| ▸ | LMNA | P02545 | 5/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | GALR2 | O43603 | 1/20 | 0.38 |
| ▸ | MITF | O75030 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | XBP1 | P17861 | 1/20 | 0.38 |
| ▸ | CCR6 | P51684 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.38 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.38 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.38 |
| ▸ | FLT1 | P17948 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1822004 | 0.86 | CYP1A2 (0.42) | MAPTALDH1A1SMN1; SMN2POLBPDGFRB | |
| SCHEMBL12627940 | 0.85 | ALDH1A1 (0.48) | MAPTLMNAALDH1A1KDM4EGAA | |
| SCHEMBL1821387 | 0.77 | ALDH1A1 (0.53) | MAPTALDH1A1PDGFRBFGFR1PDGFRA | |
| SCHEMBL28490193 | 0.70 | ALDH1A1 (0.52) | MAPTLMNAALDH1A1KDM4EGAA | |
| SCHEMBL26113637 | 0.69 | MAPT (0.54) | MAPTLMNAALDH1A1KDM4ETDP1 | |
| SCHEMBL16792433 | 0.69 | SRD5A2 (0.46) | MAPTLMNAALDH1A1KDM4EGAA | |
| SCHEMBL12580606 | 0.69 | ALDH1A1 (0.54) | MAPTALDH1A1GAASMN1; SMN2POLB | |
| SCHEMBL17675673 | 0.69 | MAPT (0.53) | MAPTLMNAALDH1A1KDM4ETDP1 | |
| SCHEMBL8196433 | 0.68 | LMNA (0.72) | MAPTLMNAALDH1A1KDM4ETDP1 | |
| SCHEMBL2368899 | 0.68 | MAPT (0.45) | MAPTLMNAALDH1A1KDM4ETDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1951042-B1 | SPIROLACTAM TRICYCLIC CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME (US) | 2012-10-10 | — | — | EP | disclosed |
| EP-1951051-B1 | SPIROHYDANTOIN TRICYCLIC CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME (US) | 2012-10-03 | — | — | EP | disclosed |
| US-7968540-B2 | Spirohydantoin tricyclic CGRP receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2011-06-28 | — | — | US | disclosed |
| US-7947677-B2 | Spirolactam tricyclic CGRP receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2011-05-24 | — | — | US | disclosed |
| US-20090281080-A1 | Spirohydantoin Tricyclic CGRP Receptor Antagonists | MERCK SHARP & DOHME LLC | 2009-11-12 | — | — | US | disclosed |
| US-20090105219-A1 | Spirolactam Tricyclic CGRP Receptor Antagonists | MERCK SHARP & DOHME LLC | 2009-04-23 | — | — | US | disclosed |
| EP-1951051-A2 | SPIROHYDANTOIN TRICYCLIC CGRP RECEPTOR ANTAGONISTS | Merck & Co., Inc. (US) | 2008-08-06 | — | — | EP | disclosed |
| EP-1951042-A2 | SPIROLACTAM TRICYCLIC CGRP RECEPTOR ANTAGONISTS | Merck & Co., Inc. (US) | 2008-08-06 | — | — | EP | disclosed |
| WO-2007061694-A2 | SPIROHYDANTOIN TRICYCLIC CGRP RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2007-05-31 | — | — | WO | disclosed |
| WO-2007061692-A2 | SPIROLACTAM TRICYCLIC CGRP RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2007-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105219-A1 | Spirolactam Tricyclic CGRP Receptor Antagonists | BDKRB1, CALCRL, BDKRB2 | MAPT 2165/4885LMNA 569/4885ALDH1A1 962/4885 |
| US-20090281080-A1 | Spirohydantoin Tricyclic CGRP Receptor Antagonists | BDKRB1, BDKRB2, CCKBR | MAPT 2782/4885LMNA 993/4885ALDH1A1 1140/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.